FDA Clearance Tracker · P010031-S513
AMPLIA MRI/AMPLIA MRI QUAD CRT-D SURESCAN; COMPIA MRI/COMPIA MRI QUAD CRT-D SURESCAN
Last checked: Nov 20, 2026Latest source record: Feb 1, 2016 (this decision)Source: openFDAMethods & limitations
Decided
Feb 1, 2016
Approved
Time to decision
130 days
Received Sep 24, 2015. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P010031-S513
- Device name
- AMPLIA MRI/AMPLIA MRI QUAD CRT-D SURESCAN; COMPIA MRI/COMPIA MRI QUAD CRT-D SURESCAN
- Applicant location
- Mounds View, MN
- Received
- Sep 24, 2015
- Decided
- Feb 1, 2016
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Change Design/Components/Specifications/Material
- Original approval
- P010031
Device type
- Device type
- Defibrillator, automatic implantable cardioverter, with cardiac resynchronization (CRT-D) (NIK)
- Device class
- Class III
- Specialty
- CardiologyElectrophysiology
FDA's approval statement
As written in FDA's record.
Approval for the Amplia MRI/Amplia MRI Quad CRT-D SureScan and Compia MRI/Compia MRI Quad CRT-D SureScan devices, programmer application software Model SW034 and extension of MR Conditional labeling for the Attain Ability and Attain Performa lead models as MRI SureScan labeled leads.
Source documents
Other decisions for Medtronic Cardiac Rhythm Disease Management
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.